MA55037A - Variants d'arn polymérase pour le coiffage co-transcriptionnel - Google Patents

Variants d'arn polymérase pour le coiffage co-transcriptionnel

Info

Publication number
MA55037A
MA55037A MA055037A MA55037A MA55037A MA 55037 A MA55037 A MA 55037A MA 055037 A MA055037 A MA 055037A MA 55037 A MA55037 A MA 55037A MA 55037 A MA55037 A MA 55037A
Authority
MA
Morocco
Prior art keywords
styling
transcriptional
rna polymerase
polymerase variants
variants
Prior art date
Application number
MA055037A
Other languages
English (en)
French (fr)
Inventor
Athanasios Dousis
Margaret Franklin
Michelle Lynn Hall
Amy E Rabideau
Kanchana Ravichandran
Kevin Smith
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MA55037A publication Critical patent/MA55037A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/1247DNA-directed RNA polymerase (2.7.7.6)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • C12Y207/07006DNA-directed RNA polymerase (2.7.7.6)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA055037A 2019-02-20 2020-02-19 Variants d'arn polymérase pour le coiffage co-transcriptionnel MA55037A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962808182P 2019-02-20 2019-02-20
US201962832314P 2019-04-11 2019-04-11
US201962885928P 2019-08-13 2019-08-13

Publications (1)

Publication Number Publication Date
MA55037A true MA55037A (fr) 2021-12-29

Family

ID=72143648

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055037A MA55037A (fr) 2019-02-20 2020-02-19 Variants d'arn polymérase pour le coiffage co-transcriptionnel

Country Status (10)

Country Link
US (3) US11485960B2 (enExample)
EP (1) EP3927821A4 (enExample)
JP (2) JP2022521094A (enExample)
KR (1) KR20210142636A (enExample)
CN (1) CN113795579A (enExample)
AU (1) AU2020224103A1 (enExample)
CA (1) CA3130888A1 (enExample)
MA (1) MA55037A (enExample)
MX (1) MX2021010075A (enExample)
WO (1) WO2020172239A1 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4023249T3 (pl) 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
AU2016341309A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Cancer vaccines
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
WO2017070601A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
MA49914A (fr) 2017-08-18 2021-04-21 Modernatx Inc Procédés analytiques par hplc
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
AU2020224103A1 (en) 2019-02-20 2021-09-16 Modernatx, Inc. Rna polymerase variants for co-transcriptional capping
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CN113874502A (zh) 2019-03-11 2021-12-31 摩登纳特斯有限公司 补料分批体外转录方法
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
CN112921014B (zh) * 2019-12-05 2023-01-06 左炽健 T7RNA聚合酶突变体、mRNA、基因、表达载体及细胞
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CA3198727A1 (en) * 2020-10-20 2022-04-28 St Pharm Co., Ltd. Oligonucleotide for 5'-capped rna synthesis
EP4274607A1 (en) 2021-01-11 2023-11-15 ModernaTX, Inc. Seasonal rna influenza virus vaccines
US20240299520A1 (en) * 2021-02-09 2024-09-12 Virginia Commonwealth University Mini circular rna therapeutics and vaccines and methods of use thereof
WO2022212442A1 (en) * 2021-03-31 2022-10-06 Modernatx, Inc. Synthesis of trinucleotide and tetranucleotide caps for mrna production
JP2024512780A (ja) 2021-04-01 2024-03-19 モデルナティエックス インコーポレイテッド 多価rna組成物中のrna種の識別及び比率決定のための方法
JP2024514182A (ja) 2021-04-13 2024-03-28 モデルナティエックス インコーポレイテッド 呼吸器ウイルス組み合わせワクチン
WO2022221440A1 (en) 2021-04-14 2022-10-20 Modernatx, Inc. Influenza-coronavirus combination vaccines
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
US20240218353A1 (en) 2021-06-17 2024-07-04 Modernatx, Inc. Alternative rna purification strategies
EP4384613A1 (en) 2021-08-13 2024-06-19 ModernaTX, Inc. Multicolumn chromatography mrna purification
EP4426853A1 (en) 2021-11-01 2024-09-11 ModernaTX, Inc. Mass spectrometry of mrna
WO2023081311A1 (en) 2021-11-05 2023-05-11 Modernatx, Inc. Methods of purifying dna for gene synthesis
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
US20250084397A1 (en) 2022-01-04 2025-03-13 Modernatx, Inc. Methods of purifying dna for gene synthesis
EP4463545A1 (en) 2022-01-14 2024-11-20 ModernaTX, Inc. In vitro transcription dna purification and recycling
EP4508242A1 (en) 2022-04-11 2025-02-19 ModernaTX, Inc. Detection of mrna purity in a mixture
EP4508201A1 (en) * 2022-04-14 2025-02-19 ModernaTX, Inc. Rna polymerase variants
US20250251391A1 (en) 2022-04-15 2025-08-07 Modernatx, Inc. Ribosomal engagement potency assay
EP4525830A1 (en) 2022-05-17 2025-03-26 ModernaTX, Inc. Preparation of highly concentrated mrna
WO2023230481A1 (en) 2022-05-24 2023-11-30 Modernatx, Inc. Orthopoxvirus vaccines
WO2023250119A1 (en) 2022-06-24 2023-12-28 Modernatx, Inc. Methods of producing rna
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024010993A1 (en) 2022-07-06 2024-01-11 Modernatx, Inc. Primer design for cell-free dna production
EP4562141A1 (en) 2022-07-28 2025-06-04 ModernaTX, Inc. Methods of rna purification
CN121737080A (zh) * 2023-03-01 2026-03-27 南京诺唯赞生物科技股份有限公司 Rna聚合酶变体、其制备方法及其在rna合成中的应用
WO2024191860A2 (en) 2023-03-10 2024-09-19 Modernatx, Inc. Nucleic acid influenza vaccines and respiratory virus combination vaccines
WO2024206835A1 (en) 2023-03-30 2024-10-03 Modernatx, Inc. Circular mrna and production thereof
WO2024232914A1 (en) * 2023-05-05 2024-11-14 Trilink Biotechnologies, Llc In vitro transcription method
EP4709849A1 (en) * 2023-05-12 2026-03-18 Codexis, Inc. Rna polymerase variants
WO2024235228A1 (zh) * 2023-05-15 2024-11-21 武汉瀚海新酶生物科技有限公司 一种性能提升的rna聚合酶突变体
WO2024263826A1 (en) 2023-06-22 2024-12-26 Modernatx, Inc. Sars-cov-2 t cell vaccines
WO2025019352A2 (en) 2023-07-14 2025-01-23 Modernatx, Inc. Mers-cov mrna vaccines
CN118755694B (zh) * 2023-07-20 2025-03-11 上海金斯康生物科技有限公司 一种功能改进的t7 rna聚合酶变体
WO2025034612A1 (en) 2023-08-04 2025-02-13 Modernatx, Inc. Varicella-zoster virus mrna vaccine
CN119490973B (zh) * 2023-08-15 2025-08-19 南京诺唯赞生物科技股份有限公司 提高体外转录中rna加帽率的rna聚合酶变体
WO2025152833A1 (zh) * 2024-01-19 2025-07-24 南京诺唯赞生物科技股份有限公司 Rna聚合酶变体及其应用
US12492420B2 (en) 2024-03-29 2025-12-09 New England Biolabs, Inc. Compositions, kits, and methods for in vitro transcription
CN120775820A (zh) * 2024-04-07 2025-10-14 南京诺唯赞生物科技股份有限公司 Rna聚合酶变体
GB202406294D0 (en) 2024-05-06 2024-06-19 Thermo Fisher Scientific Baltics Uab Methods and compositions for producing capped mRNA
WO2025250938A2 (en) 2024-05-31 2025-12-04 Modernatx, Inc. Respiratory syncytial virus and metapneumovirus vaccines
CN121160664B (zh) * 2024-06-17 2026-04-24 南京诺唯赞生物科技股份有限公司 Rna聚合酶变体
CN119464247B (zh) * 2025-01-13 2025-07-11 苏州近岸蛋白质科技股份有限公司 一种t7 rna聚合酶突变体及其应用
CN121294389A (zh) * 2025-07-17 2026-01-09 南京诺唯赞生物科技股份有限公司 Rna聚合酶变体及其应用

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2279673A1 (en) 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acids for therapeutic and diagnostic uses
FR2822164B1 (fr) 2001-03-19 2004-06-18 Centre Nat Rech Scient Polypeptides derives des arn polymerases, et leurs utilisations
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
EP2010659B1 (en) 2006-04-14 2014-06-18 CellScript, Inc. Kits and methods for generating 5' capped RNA
WO2009021191A2 (en) * 2007-08-08 2009-02-12 Barnes Wayne M Improved t7 expression system
JP2011521626A (ja) * 2008-05-02 2011-07-28 エピセンター テクノロジーズ コーポレーション Rnaポリホスファターゼの組成物、キットおよびそれらの使用
JP5625908B2 (ja) * 2008-08-08 2014-11-19 東ソー株式会社 機能改善したrnaポリメラーゼ変異体
PL2467158T3 (pl) * 2009-08-21 2017-07-31 Merial, Inc. Rekombinowana szczepionka z paramyksowirusem ptaków oraz sposób jej wytwarzania i zastosowania
JP2011223982A (ja) 2010-03-30 2011-11-10 Tosoh Corp T7rnaポリメラーゼ融合蛋白質
EP2377938A1 (en) 2010-04-16 2011-10-19 Eukarys Capping-prone RNA polymerase enzymes and their applications
US9193959B2 (en) * 2010-04-16 2015-11-24 Roche Diagnostics Operations, Inc. T7 RNA polymerase variants with enhanced thermostability
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN103703141B (zh) 2011-04-08 2016-08-17 伯乐实验室公司 具有降低的非特异性活性的pcr反应混合物
CA2835428A1 (en) 2011-05-17 2012-11-22 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof for non-human vertebrates
EP3587573A1 (en) * 2011-06-16 2020-01-01 The Regents of The University of California Synthetic gene clusters
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013039861A2 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
FR2981088B1 (fr) * 2011-10-06 2013-11-29 Biomerieux Sa Arn polymerases mutees
WO2013130161A1 (en) 2011-12-14 2013-09-06 modeRNA Therapeutics Methods of responding to a biothreat
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
CN104968354A (zh) 2011-12-21 2015-10-07 现代治疗公司 增加器官或器官外植体的活力或寿命的方法
EP3144389B1 (en) 2011-12-30 2018-05-09 Cellscript, Llc Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
US9045740B2 (en) 2012-02-24 2015-06-02 University Of Massachusetts Modified T7-related RNA polymerases and methods of use thereof
WO2013148867A1 (en) * 2012-03-27 2013-10-03 Massachusetts Institute Of Technology Artificial sigma factors based on bisected t7 rna polymerase
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
WO2014028429A2 (en) * 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
US20150376581A1 (en) * 2012-10-29 2015-12-31 Technische Universitaet Dortmund T7 rna polymerase variants and methods of using the same
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
WO2014093574A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014152027A1 (en) * 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
CA2917348A1 (en) 2013-07-11 2015-01-15 Moderna Therapeutics, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
AU2014337156A1 (en) 2013-10-18 2016-05-12 Modernatx, Inc. Compositions and methods for tolerizing cellular systems
PL4023249T3 (pl) 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
CA2955375A1 (en) 2014-07-17 2016-01-21 Modernatx, Inc. Terminal modifications of polynucleotides
EP3247363A4 (en) 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
EP3303575B1 (en) 2015-05-29 2022-03-16 CureVac AG Method for adding cap structures to rna using immobilized enzymes
WO2016201377A1 (en) 2015-06-10 2016-12-15 Moderna Therapeutics, Inc. Targeted adaptive vaccines
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
WO2017015457A1 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
US20190008887A1 (en) 2015-07-30 2019-01-10 ModernaTX Inc. Multimeric mrna
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017031241A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Rna mapping/fingerprinting
JP6948313B6 (ja) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物および組成物
CN120842296A (zh) * 2015-09-21 2025-10-28 垂林克生物技术有限公司 用于合成5’-加帽rna的组合物和方法
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
JP6997704B2 (ja) 2015-10-14 2022-02-04 トランスレイト バイオ, インコーポレイテッド 生産性向上のためのrna関連酵素の修飾
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
EA201891000A1 (ru) 2015-10-22 2018-12-28 МОДЕРНАТиЭкс, ИНК. Вакцина против респираторно-синцитиального вируса
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
WO2017070601A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
EP3365009A4 (en) 2015-10-22 2019-07-03 ModernaTX, Inc. VACCINES AGAINST HERPES SIMPLEX VIRUS
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
JP7384512B2 (ja) 2015-10-22 2023-11-21 モデルナティエックス インコーポレイテッド 広域インフルエンザウイルスワクチン
AU2016341309A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Cancer vaccines
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
MA43568A (fr) 2015-12-17 2018-11-14 Modernatx Inc Polynucléotides codant pour la méthylmalonyl-coa mutase
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
CN116144626A (zh) * 2016-01-13 2023-05-23 新英格兰生物实验室公司 T7 rna聚合酶的热稳定变体
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017201317A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
MA45036A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
WO2017201328A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
JP2019519516A (ja) 2016-05-18 2019-07-11 モデルナティーエックス, インコーポレイテッド がんの治療のためのmRNA併用療法
US11001861B2 (en) 2016-05-18 2021-05-11 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
JP2019519601A (ja) 2016-05-18 2019-07-11 モダーナティエックス・インコーポレイテッドModernaTX, Inc. 急性間欠性ポルフィリン症の治療のためのポルホビリノゲン脱アミノ酵素をコードするポリヌクレオチド
EP3458108A4 (en) 2016-05-18 2020-04-22 ModernaTX, Inc. POLYNUCLEOTIDES ENCODING A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
IL263079B2 (en) 2016-05-18 2024-05-01 Modernatx Inc Polynucleotides encoding relaxin
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
US12123030B2 (en) 2016-05-18 2024-10-22 Modernatx, Inc. Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
WO2017218704A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN106244608B (zh) * 2016-08-08 2019-10-25 中国科学技术大学 诱导的t7 rna聚合酶
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
WO2018081462A1 (en) 2016-10-26 2018-05-03 Modernatx, Inc. Methods and compositions for rna mapping
CN110402145A (zh) 2016-10-26 2019-11-01 莫得纳特斯公司 用于增强免疫应答的信使核糖核酸及其使用方法
US10907165B2 (en) 2016-10-31 2021-02-02 Cornell University Methods of enhancing translation ability and stability of RNA molecules, treatments, and kits
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
US20180243225A1 (en) 2017-01-25 2018-08-30 Modernatx, Inc. Ebola/marburg vaccines
BR112019015797A2 (pt) 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
US20190351040A1 (en) 2017-02-01 2019-11-21 Modernatx, Inc. Rna cancer vaccines
EP3577221A4 (en) 2017-02-01 2020-12-23 ModernaTX, Inc. Polynucleotide secondary structure
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
WO2018157009A1 (en) 2017-02-24 2018-08-30 Modernatx, Inc. Nucleic acid-based therapy of muscular dystrophies
EP4186888B1 (en) 2017-03-15 2025-11-26 ModernaTX, Inc. Compound and compositions for intracellular delivery of therapeutic agents
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
WO2018175783A1 (en) 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
WO2018200737A1 (en) 2017-04-26 2018-11-01 Modernatx, Inc. Herpes simplex virus vaccine
WO2018232355A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna antibodies
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
KR20250028535A (ko) * 2017-06-30 2025-02-28 코덱시스, 인코포레이티드 T7 rna 폴리머라제 변이체
EP3645712A4 (en) * 2017-06-30 2021-07-07 Codexis, Inc. T7 RNA POLYMERASE VARIANTS
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
US20200254086A1 (en) 2017-08-18 2020-08-13 Moderna TX, Inc. Efficacious mrna vaccines
MA49914A (fr) 2017-08-18 2021-04-21 Modernatx Inc Procédés analytiques par hplc
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
US20190192646A1 (en) 2017-11-03 2019-06-27 Modernatx, Inc. Salmonella vaccines
MA50813A (fr) 2017-11-21 2020-09-30 Modernatx Inc Vaccins contre le virus d'epstein-barr
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
AU2019293244B2 (en) 2018-06-27 2026-04-02 Modernatx, Inc. Personalized cancer vaccine epitope selection
CA3111836A1 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
MA54192A (fr) 2018-11-07 2021-09-15 Modernatx Inc Vaccins à arn contre le cancer
CN118697900A (zh) 2019-01-31 2024-09-27 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
AU2020224103A1 (en) 2019-02-20 2021-09-16 Modernatx, Inc. Rna polymerase variants for co-transcriptional capping
CN113874502A (zh) * 2019-03-11 2021-12-31 摩登纳特斯有限公司 补料分批体外转录方法
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
US20220236253A1 (en) 2019-05-31 2022-07-28 Modernatx, Inc. Expanded t cell assay
CN114269918A (zh) 2019-08-14 2022-04-01 摩登纳特斯有限公司 用于纯化体外转录的下游产物的方法
CA3154082A1 (en) 2019-09-11 2021-03-18 Modernatx, Inc. Human cytomegalovirus vaccine
WO2021055811A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Cap guides and methods of use thereof for rna mapping
EP4088281A4 (en) 2020-01-10 2024-02-21 ModernaTX, Inc. VARIOUS AUTOCECODER FOR GENERATING BIOLOGICAL SEQUENCE
US20210228707A1 (en) 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines
JP2023513073A (ja) 2020-01-30 2023-03-30 モデルナティエックス インコーポレイテッド 呼吸器系ウイルス免疫化組成物
BR112022015565A2 (pt) 2020-02-07 2022-09-27 Modernatx Inc Vacinas de domínio de mrna para sars-cov-2
WO2021211343A1 (en) 2020-04-13 2021-10-21 Modernatx, Inc. Zika virus mrna vaccines
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
EP4149485A4 (en) 2020-05-15 2024-10-23 ModernaTX, Inc. RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION AND METHODS OF USE THEREOF FOR THE TREATMENT OF COVID-19
EP4153238A4 (en) 2020-05-21 2024-12-18 ModernaTX, Inc. METHYLENE BLUE STABILIZED MRNA COMPOSITIONS
CA3185855A1 (en) 2020-06-05 2021-12-09 Modernatx, Inc. Bacterial strains for dna production
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
EP4217371A1 (en) 2020-09-25 2023-08-02 ModernaTX, Inc. Multi-proline-substituted coronavirus spike protein vaccines
EP4274607A1 (en) 2021-01-11 2023-11-15 ModernaTX, Inc. Seasonal rna influenza virus vaccines
JP2024503699A (ja) 2021-01-15 2024-01-26 モデルナティエックス インコーポレイテッド バリアント株ベースのコロナウイルスワクチン
WO2022155524A1 (en) 2021-01-15 2022-07-21 Modernatx, Inc. Variant strain-based coronavirus vaccines
EP4301405A4 (en) 2021-03-05 2025-01-29 ModernaTX, Inc. ENTEROVIRAL VACCINES WITH VIRUS-LIKE PARTICLES (VLP)
EP4313072A1 (en) 2021-03-26 2024-02-07 ModernaTX, Inc. Pertussis vaccine
WO2022212442A1 (en) 2021-03-31 2022-10-06 Modernatx, Inc. Synthesis of trinucleotide and tetranucleotide caps for mrna production
JP2024512780A (ja) 2021-04-01 2024-03-19 モデルナティエックス インコーポレイテッド 多価rna組成物中のrna種の識別及び比率決定のための方法
WO2022212191A1 (en) 2021-04-01 2022-10-06 Modernatx, Inc. Mucosal expression of antibody structures and isotypes by mrna
EP4322997A4 (en) 2021-04-13 2025-02-26 ModernaTX, Inc. EPSTEIN-BARR VIRUS mRNA VACCINES
JP2024514182A (ja) 2021-04-13 2024-03-28 モデルナティエックス インコーポレイテッド 呼吸器ウイルス組み合わせワクチン
WO2022221336A1 (en) 2021-04-13 2022-10-20 Modernatx, Inc. Respiratory syncytial virus mrna vaccines
WO2022221440A1 (en) 2021-04-14 2022-10-20 Modernatx, Inc. Influenza-coronavirus combination vaccines
WO2022232585A1 (en) 2021-04-29 2022-11-03 Modernatx, Inc. Lyophilization methods for preparing lipid formulated therapeutics

Also Published As

Publication number Publication date
US20250171751A1 (en) 2025-05-29
CN113795579A (zh) 2021-12-14
US20230104080A1 (en) 2023-04-06
AU2020224103A1 (en) 2021-09-16
EP3927821A4 (en) 2023-01-25
JP2022521094A (ja) 2022-04-05
KR20210142636A (ko) 2021-11-25
WO2020172239A1 (en) 2020-08-27
US11485960B2 (en) 2022-11-01
EP3927821A1 (en) 2021-12-29
US12180518B2 (en) 2024-12-31
MX2021010075A (es) 2021-12-10
CA3130888A1 (en) 2020-08-27
JP2025072570A (ja) 2025-05-09
US20210309976A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
MA55037A (fr) Variants d'arn polymérase pour le coiffage co-transcriptionnel
EP3668971A4 (en) RNA POLYMERASE VARIANTS
EP3532613A4 (en) METHOD AND COMPOSITIONS FOR RNA MAPPING
MA49421A (fr) Formulations d'arn
EP3890786A4 (en) RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR FOR GENE RELEASE
EP3852956A4 (en) TECHNIQUES TO IMPROVE MHD BEAM PERFORMANCE
IL282456A (en) Engineered dna polymerase variants
EP3512863A4 (en) 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF RNA VIRUSES
EP3589646A4 (en) CD19 COMPOSITIONS AND PROCEDURES FOR IMMUNOTHERAPY
MA47606A (fr) Procédés de purification d'arn messager
EP3801775A4 (en) SELF-CURING ACRYLIC HAIR STYLING COMPOSITION
EP3310395A4 (en) RNA-guided transcription regulation and method for the use thereof for the treatment of back pain
EP3717505A4 (en) GENENICALLY MODIFIED DNA-BINDING PROTEINS
MA54503A (fr) Arn codant pour une protéine
EP3915009A4 (en) COALESCING OPERAND REGISTER FILE FOR GPUS
EP3690047A4 (en) ARTIFICIAL GENOME MANIPULATION FOR GENE EXPRESSION REGULATION
EP3820490A4 (en) AAV COMPOSITIONS
EP3755801A4 (en) SHORT/SMALL HAIRPIN RNA MOLECULES
EP4069830A4 (en) Engineering circular guide rnas
EP3628003A4 (en) P-ETHOXY-NUCLEIC ACIDS FOR IGF-1R INHIBITION
EP3612159A4 (en) P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION
EP3698164A4 (en) LANE CHANGE ASSISTANCE IMPROVEMENTS
MA53238A (fr) Formules d'ag10
EP3516565A4 (en) TUNING ASSOCIATIONS FOR PREDICTIVE GENE ASSESSMENT
EP3827099A4 (en) SMALL RNA PREDICTORS OF ALZHEIMER'S DISEASE